Cristina Jiménez Luna-rekin lankidetzan egindako argitalpenak (9)

2019

  1. O6-methylguanine-DNA methyltransferase promoter methylation in patients with rectal adenocarcinoma after chemoradiotherapy treatment: Clinical implications

    Balkan Medical Journal, Vol. 36, Núm. 5, pp. 283-286

  2. Untargeted LC-HRMS-based metabolomics to identify novel biomarkers of metastatic colorectal cancer

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers

    PLoS ONE, Vol. 13, Núm. 4

  2. Proteomic biomarkers in body fluids associated with pancreatic cancer

    Oncotarget, Vol. 9, Núm. 23, pp. 16573-16587

2017

  1. Untargeted LC-HRMS-based metabolomics for searching new biomarkers of pancreatic ductal adenocarcinoma: A pilot study

    SLAS Discovery, Vol. 22, Núm. 4, pp. 348-359

2016

  1. Current status of immunotherapy treatments for pancreatic cancer

    Journal of Clinical Gastroenterology, Vol. 50, Núm. 10, pp. 836-848

  2. Identification of gene expression profiling associated with erlotinib-related skin toxicity in pancreatic adenocarcinoma patients

    Toxicology and Applied Pharmacology, Vol. 311, pp. 113-116

  3. Last advances in nanocarriers-based drug delivery systems for colorectal cancer

    Current Drug Delivery, Vol. 13, Núm. 6, pp. 830-838

2014

  1. Transcriptional Profiling of Peripheral Blood in Pancreatic Adenocarcinoma Patients Identifies Diagnostic Biomarkers

    Digestive Diseases and Sciences, Vol. 59, Núm. 11, pp. 2714-2720